RecruitingPhase 3NCT07285291

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Sponsor

Taisho Pharmaceutical Co., Ltd.

Enrollment

100 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Hyperphosphatemia Patients on Hemodialysis

Summary

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called TS-172 20~60 mg/day for people with hyperphosphatemia patients on hemodialysis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTS-172 20~60 mg/day

oral administration of TS-172 20\~60 mg/day

DRUGPlacebo

oral administration of placebo

Locations(1)

Taisho Pharmaceutical Co., Ltd selected site

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07285291

Related Trials

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT075488401 location

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT072853041 location